glucaric acid has been researched along with ferric carboxymaltose in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.88) | 29.6817 |
| 2010's | 32 (94.12) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birgegård, G; Hedenus, M | 1 |
| García-Erce, JA; Gómez-Ramírez, S; Muñoz, M | 1 |
| Bregman, DB; Butcher, A; Goodnough, LT; Harrington, RA; Koch, TA; Morris, D; Onken, JE; Szczech, LA; Wolf, M | 1 |
| Bager, P; Dahlerup, JF | 1 |
| Bokemeyer, B; Chopey, IV; Evstatiev, R; Gasche, C; Gutzwiller, FS; Iqbal, T; Khalif, IL; Marteau, P; Riopel, L; Stein, J | 1 |
| Gisbert, JP; Gomollón, F | 1 |
| Bisbe, E; Díez-Lobo, AI; García-Erce, JA; Muñoz, M | 1 |
| Angerosa, M; Cao, G; Oliveri, L; Toblli, JE | 1 |
| Christoph, P; Pfenniger, A; Schuller, C; Surbek, D | 1 |
| Bhandari, S; Muñoz, M; Reinisch, W; Staun, M | 1 |
| Christoph, P; De Tejada, BM; Irion, O; Schuller, C; Studer, H; Surbek, D | 1 |
| Hutchings, A; Jeans, A; Macdougall, IC; Wilson, PD | 1 |
| Biggar, P; Hahn, KM | 1 |
| Bailie, GR; Leggett, RE; Levin, R; Li, H; Li, HD; Patadia, H; Schuler, C | 1 |
| Amet, S; Deray, G; Janus, N; Launay-Vacher, V; Mahi, L; Rey, JB; Rouillon, L; Scotte, F; Zakin, L | 1 |
| Münch, HG; Potthoff, SA | 1 |
| Achermann, R; Giger, M | 1 |
| Bregman, DB; Buerkert, J; Butcher, A; Goodnough, LT; Hamerski, D; Harrington, RA; Iftikhar, H; Koch, TA; Mangoo-Karim, R; Martin, ER; Martinez, CO; Morris, D; Newman, GE; Onken, JE; Qunibi, WY; Ross, DL; Singh, B; Smith, MT | 1 |
| Braunhofer, P; Brock, E; Schneider, H; Troxler, J | 1 |
| Angerosa, M; Cao, G; Dominici, FP; Giani, JF; Toblli, JE | 1 |
| Cornelius, C; Goldenberg, H; Haider, K; Praschberger, M; Scheiber-Mojdehkar, B; Schitegg, M; Sturm, B | 1 |
| Connor, JR; Nixon, AM; Perno, JR; Webb, B; Zhang, X | 1 |
| Bhatla, N; Kachhawa, G; Kriplani, A; Mahey, R; Mogili, KD; Saxena, R | 1 |
| Crumbliss, AL; Gupta, A; Pratt, RD | 1 |
| Fell, LH; Fliser, D; Heine, GH; Rotter, B; Seiler-Mußler, S; Sellier, AB; Sester, M; Winter, P; Zawada, AM | 1 |
| Macdougall, IC | 1 |
| Coyne, DW; Daloul, R; Pandey, R | 1 |
| Lopes, AI; Maltez, C; Valério de Azevedo, S | 1 |
| Bansal, SS; Huang, L; Kent, AB; Lee, D; Macdougall, IC; MacGinley, R; McMahon, LP; Roberts, MA; Troster, SM | 1 |
| Berger, SP; Daha, MR; de Vlaam, TP; Franssen, CF; Gaillard, CA; Gaya da Costa, M; Hempel, JC; Poppelaars, F; Seelen, MA | 1 |
| Bugat, R; Duvillié, L; Espié, M; Luporsi, E; Perot, S; Pithois Merli, I; Scotté, F; Spaeth, D; Toledano, A | 1 |
| Muduma, G; Pollock, RF | 1 |
| Catarinolo, M; Enzmann, H; Fütterer, S; Langguth, P; Schlösser, C; Schnorr, J; Spicher, K | 1 |
| Abergel, A; Aumaitre, O; Bagel, S; Boisgard, S; Delpeuch, A; Ruivard, M; Sautou, V | 1 |
7 review(s) available for glucaric acid and ferric carboxymaltose
| Article | Year |
|---|---|
The role of iron supplementation during epoietin treatment for cancer-related anemia.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Drug Administration Schedule; Erythropoiesis; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Iron Compounds; Iron-Dextran Complex; Iron, Dietary; Maltose; Neoplasms; Randomized Controlled Trials as Topic | 2009 |
Intravenous iron in inflammatory bowel disease.
Topics: Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Gluconates; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Injections, Intraventricular; Iron; Iron-Dextran Complex; Maltose; Treatment Outcome | 2009 |
State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease.
Topics: Algorithms; Anemia, Iron-Deficiency; Clinical Trials as Topic; Diagnosis, Differential; Disaccharides; Dose-Response Relationship, Drug; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron Deficiencies; Maltose; Prevalence; Thrombocytosis; Thromboembolism | 2013 |
[Importance of the different i.v. iron generations for everyday medical practice].
Topics: Anemia, Iron-Deficiency; Disaccharides; Dose-Response Relationship, Drug; Drug Substitution; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Humans; Infusions, Intravenous; Iron-Dextran Complex; Maltose; Structure-Activity Relationship; Treatment Outcome | 2013 |
[Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
Topics: Administration, Oral; Anaphylaxis; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Humans; Infusions, Intravenous; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Oxidative Stress; Renal Dialysis | 2013 |
Iron Treatment Strategies in Nondialysis CKD.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrous Compounds; Glucaric Acid; Hematinics; Hemoglobins; Humans; Iron Compounds; Maltose; Renal Insufficiency, Chronic; Severity of Illness Index; Transferrin | 2016 |
Iron Treatment Strategies in Dialysis-Dependent CKD.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Hemoglobins; Humans; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Renal Dialysis; Transferrin | 2016 |
5 trial(s) available for glucaric acid and ferric carboxymaltose
| Article | Year |
|---|---|
Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Biomarkers; Cardiovascular Diseases; Chronic Disease; Female; Ferric Compounds; Ferric Oxide, Saccharated; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucaric Acid; Hemoglobins; Humans; Kidney Diseases; Male; Maltose; Middle Aged; Risk Factors; Sucrose; Treatment Outcome | 2010 |
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Comorbidity; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Male; Maltose; Middle Aged; Outcome Assessment, Health Care; Treatment Outcome; Young Adult | 2011 |
Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
Topics: Aged; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glomerular Filtration Rate; Glucaric Acid; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Iron; Male; Maltose; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Hematinics; Hemoglobins; Humans; India; Maltose; Middle Aged; Prospective Studies; Treatment Outcome; Uterine Hemorrhage | 2016 |
Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Female; Ferric Compounds; Ferric Oxide, Saccharated; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucaric Acid; Hematinics; Humans; Male; Maltose; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
22 other study(ies) available for glucaric acid and ferric carboxymaltose
| Article | Year |
|---|---|
The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Drug Costs; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Health Care Costs; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Male; Maltose; Middle Aged; Young Adult | 2010 |
IBD: Intravenous iron in IBD--what's the best preparation?
Topics: Anemia, Iron-Deficiency; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Inflammatory Bowel Diseases; Injections, Intravenous; Maltose; Quality of Life; Treatment Outcome | 2011 |
A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Costs and Cost Analysis; Elective Surgical Procedures; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Injections, Intravenous; Male; Maltose; Middle Aged; Preoperative Care | 2011 |
Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Topics: Animals; Antioxidants; Blood Pressure; Creatinine; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Heart; Hematinics; Immunohistochemistry; Inflammation; Injections, Intravenous; Iron-Dextran Complex; Kidney; Lipid Peroxidation; Liver; Magnetite Nanoparticles; Male; Maltose; Molecular Weight; Oxidative Stress; Proteinuria; Rats; Rats, Sprague-Dawley | 2011 |
Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Blood Transfusion; Cohort Studies; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Injections, Intravenous; Maltose; Puerperal Disorders; Retrospective Studies; Treatment Outcome | 2012 |
Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Topics: Administration, Intravenous; Adolescent; Adult; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Maltose; Middle Aged; Pregnancy; Pregnancy Complications, Hematologic; Retrospective Studies; Young Adult | 2012 |
An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
Topics: Administration, Intravenous; Ambulatory Care Facilities; Anemia, Iron-Deficiency; Clinical Protocols; Costs and Cost Analysis; Decision Support Techniques; Efficiency, Organizational; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hospitalization; Humans; Maltose; Patient Preference; Renal Insufficiency, Chronic; Transportation; United Kingdom | 2013 |
Oxidative effect of several intravenous iron complexes in the rat.
Topics: Administration, Intravenous; Animals; Dinitrobenzenes; Dose-Response Relationship, Drug; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Iron-Dextran Complex; Maltose; Oxidative Stress; Rats; Tissue Distribution; Tyrosine | 2013 |
Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey.
Topics: Anemia, Iron-Deficiency; Central Venous Catheters; Ferric Compounds; Ferric Oxide, Saccharated; France; Glucaric Acid; Humans; Infusions, Intravenous; Maltose; Neoplasms; Practice Patterns, Physicians'; Surveys and Questionnaires | 2013 |
[Iron substitution in outpatients in Switzerland: Increase of costs associated with intravenous administration].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia, Iron-Deficiency; Child; Child, Preschool; Cost Savings; Cross-Sectional Studies; Drug Costs; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hemoglobinometry; Humans; Infant; Infusions, Intravenous; Iron Compounds; Male; Maltose; Middle Aged; National Health Programs; Off-Label Use; Retrospective Studies; Switzerland; Young Adult | 2013 |
Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data.
Topics: Anemia, Iron-Deficiency; Budgets; Cost Savings; Drug Substitution; Female; Ferric Compounds; Ferric Oxide, Saccharated; Financing, Personal; Glucaric Acid; Humans; Maltose; National Health Programs; Switzerland | 2014 |
Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Topics: Administration, Intravenous; Animals; Apoptosis; Caspase 3; Disaccharides; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Iron-Dextran Complex; Kidney; Liver; Male; Maltose; Models, Animal; Myocardium; Rats; Tyrosine | 2015 |
Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.
Topics: Ascorbic Acid; Cell Line; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hep G2 Cells; Humans; Iron; Liver; Macrophages; Maltose | 2015 |
Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.
Topics: Animals; Cation Transport Proteins; Cell Line; Cell Survival; Disaccharides; Epithelial Cells; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrosoferric Oxide; Glucaric Acid; Hepcidins; Humans; Iron; Iron-Dextran Complex; Kidney; Lipid Peroxidation; Macrophages, Peritoneal; Maltose; Oxidative Stress; Primary Cell Culture; Rats; Tumor Necrosis Factor-alpha | 2015 |
Ferrous iron content of intravenous iron formulations.
Topics: Administration, Intravenous; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Ferrous Compounds; Glucaric Acid; Iron-Dextran Complex; Maltose | 2016 |
Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.
Topics: Anemia, Iron-Deficiency; Case-Control Studies; Cell Differentiation; Dendritic Cells; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Injections, Intravenous; Iron Compounds; Macrophages; Maltose; MicroRNAs; Monocytes; Phagocytosis | 2016 |
Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
Topics: Administration, Intravenous; Adolescent; Anemia, Iron-Deficiency; Child; Crohn Disease; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Follow-Up Studies; Glucaric Acid; Hemoglobins; Humans; Male; Maltose; Portugal; Prospective Studies; Transferrin | 2017 |
Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Complement Activation; Complement C1q; Complement C3d; Complement Membrane Attack Complex; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Humans; In Vitro Techniques; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Mannose-Binding Lectin; Properdin; Renal Dialysis | 2017 |
Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).
Topics: Adult; Aged; Anemia; Erythrocyte Transfusion; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; France; Glucaric Acid; Hematologic Neoplasms; Hemoglobins; Humans; Male; Maltose; Middle Aged; Neoplasms; Retrospective Studies | 2017 |
Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
Topics: Anemia, Iron-Deficiency; Budgets; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron-Dextran Complex; Maltose; Retrospective Studies; United Kingdom | 2017 |
Bioequivalence decision for nanoparticular iron complex drugs for parenteral administration based on their disposition.
Topics: Amylopectin; Animals; Embryo, Nonmammalian; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Iron-Dextran Complex; Kidney; Liver; Maltose; Models, Animal; Myocardium; Nanoparticles; Therapeutic Equivalency; Turkey | 2018 |
Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
Topics: Administration, Intravenous; Aged; Anemia, Iron-Deficiency; Drug Costs; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Inpatients; Length of Stay; Male; Maltose; Middle Aged; Retrospective Studies | 2018 |